

Supplementary Appendix

Trastuzumab deruxtecan induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: A systematic review

Ziad Abuhelwa, MD¹; Abdurahman Alloghbi, MD^{2,3}; Ali Alqahtani, MD⁴; Misako Nagasaka, MD, PhD^{5,6} *

¹ Department of Medicine, University of Toledo, Toledo, Ohio, USA

² Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

³ Department of Oncology, King Khalid University, Abha, Saudia Arabia

⁴ Department of Oncology, Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA

⁵ Department of Oncology, University of California Irvine, Orange, California, USA

⁶ Department of Medicine, Division of Neurology, St. Marianna University School of Medicine, Kawasaki, JAPAN

* Corresponding author

Misako Nagasaka, MD PhD

Associate Clinical Professor

Division of Hematology/Oncology, Department of Medicine

UCI Health

101 The City Drive South

Building 200, Room 410, ZOT 4061

Orange, CA 92868 nagasakm@hs.uci.edu

Supplementary 1: Incidence of confirmed T-DXd ILD/pneumonitis in the included studies according to the received dose

Author, year	Intervention	Sample size (N)	ILD/pneumonitis in N	5.4 mg/kg q3w (n)	6.4 mg/kg q3w (n)	ILD/pneumonitis in 5.4 mg/kg q3w	ILD/pneumonitis in 6.4 mg/kg q3w
Modi, 2020 [1]	T-DXd 5.4 mg/kg q3w	184	25	184	-	25	-
Cortes, 2021 [2]	T-DXd, NR dose	257	27	-	-	-	-
Modi, 2020 [3]	T-DXd 5.4 or 6.4 mg/kg q3w	54	8	21	33	0	8
Chang, 2019 [4]	T-DXd 6.4 mg/kg q3w	12	0	-	12	-	0
Tamura, 2019 [5]	T-DXd 5.4 or 6.4 mg/kg q3w	115	13 *	49 *	66 *	NR *	NR *
Yamashita, 2020 [6]	T-DXd 6.4 mg/kg q3w	51	1	-	51	-	1
Bartsch, 2021 [7]	T-DXd, NR dose	10	0	-	-	-	-
Shitara, 2020 [8]	T-DXd 6.4 mg/kg q3w	125	12	-	125	-	12
Van Cutsem, 2021 [9]	T-DXd 6.4 mg/kg q3w	79	6	-	79	-	6
Shitara, 2019 [10]	T-DXd 5.4 or 6.4 mg/kg q3w	44	1 **	19 **	25 **	NR **	NR **
Siena, 2021 [11]	T-DXd 6.4 mg/kg q3w	78	5	-	78	-	5
Hasegawa, 2021 [12]	T-DXd 6.4 mg/kg q3w	34	9	-	34	-	9
Li, 2022 [13]	T-DXd 6.4 mg/kg q3w	91	24	-	91	-	24
Tsurutani, 2020 [14]	T-DXd 6.4 mg/kg q3w	59	5	-	59	-	5

Abbreviations: T-DXd; trastuzumab deruxtecan, ILD; interstitial lung disease, q3w; every 3 weeks, NR; not reported

* 20 cases of ILD/ pneumonitis were reported by investigators (6 in 5.4 vs 14 in 6.4). Of them, 13 cases were confirmed by a committee as T-DXd related ILD. No data on number of the confirmed cases in each subgroup.

** 4 cases of ILD/pneumonitis were reported by investigators. One case was confirmed by a committee as T-DXd induced ILD. No data from which subgroup

References:

1. Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. *New England Journal of Medicine*. 2020;382(7):610-21.
2. Cortés J, Kim S, Chung W, Im S, Park Y, Hegg R, et al. LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. *Annals of Oncology*. 2021;32:S1287-S8.
3. Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. *Journal of Clinical Oncology*. 2020;38(17):1887.
4. Chang D-Y, Lin C-C, Chen TW-W, Lin C-H, Lee J-H, Chao T-C, et al. Abstract C041: Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer. *AACR*; 2019.
5. Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. *The Lancet Oncology*. 2019;20(6):816-26.
6. Yamashita T, Shimomura A, Takano T, Sagara Y, Watanabe J, Tokunaga E, et al. Abstract P1-18-12: A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer. *AACR*; 2020.
7. Bartsch R, Berghoff A, Furtner J, Bergen E, Roider-Schur S, Marhold M, et al. 280P Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial. *Annals of Oncology*. 2021;32:S486.
8. Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. *New England Journal of Medicine*. 2020;382(25):2419-30.
9. Van Cutsem E, Di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. *Annals of Oncology*. 2021;32:S1332.
10. Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. *The Lancet Oncology*. 2019;20(6):827-36.
11. Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): A multicentre, open-label, phase 2 trial. *The Lancet Oncology*. 2021;22(6):779-89.
12. Hasegawa K, Nishikawa T, Hirakawa A, Kawasaki M, Tomatsuri S, Nagasaka Y, et al. 813P Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE trial, NCCH1615): A multicenter, phase II clinical trial. *Annals of Oncology*. 2021;32:S767.
13. Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. *New England Journal of Medicine*. 2022;386(3):241-51.
14. Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. *Cancer discovery*. 2020;10(5):688-701.